"Founded by Dr. David Berz, a leading medical oncologist, Valkyrie Clinical Trials, to provide access to the most effective cancer therapies to patients of all backgrounds. The company owns and operates a cutting-edge research site in Century City and provides a variety of clinical, research, and site management services."

During the past decade, Valkyrie Clinical Trials conducted 17 clinical trials. In the 10-year time frame, 17 clinical trials started and 1 clinical trials were completed, i.e. on average, 5.9% percent of trials that started reached the finish line to date. In the past 5 years, 16 clinical trials started and 1 clinical trials were completed. i.e. 6.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Valkyrie Clinical Trials" #1 sponsor was "Inhibrx, Inc." with 3 trials, followed by "BeiGene" with 2 trials sponsored, "Boehringer Ingelheim" with 2 trials sponsored, "G1 Therapeutics, Inc." with 2 trials sponsored and "Biocept, Inc." with 2 trials sponsored. Other sponsors include 2 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Valkyrie Clinical Trials" #1 collaborator was "ICON plc" with 2 trials as a collaborator and "Merck Sharp & Dohme LLC" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 2 trials.

According to Clinical.Site data, the most researched conditions in "Valkyrie Clinical Trials" are "Non-Small Cell Lung Cancer" (3 trials), "Gastric Adenocarcinoma" (2 trials), "Melanoma" (2 trials), "NSCLC" (2 trials) and "Non-small Cell Lung Cancer" (2 trials). Many other conditions were trialed in "Valkyrie Clinical Trials" in a lesser frequency.

Most popular intervention types in "Valkyrie Clinical Trials" are "Drug" (15 trials), "Biological" (2 trials), "Other" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Pembrolizumab" (3 trials), "Placebo" (3 trials), "Ociperlimab" (2 trials), "Tislelizumab" (2 trials) and "Trilaciclib" (2 trials). Other intervention names were less common.

The vast majority of trials in "Valkyrie Clinical Trials" are 17 trials for "All" genders.

Currently, there are NaN active trials in "Valkyrie Clinical Trials". undefined are not yet recruiting, 14 are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were undefined completed trials in Valkyrie Clinical Trials, undefined suspended trials, and 2 terminated clinical trials to date.

Out of the total trials that were conducted in Valkyrie Clinical Trials, 9 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".